Sigyn Therapeutics (SIGY) Convertible Debt (2016 - 2020)

Sigyn Therapeutics has disclosed Convertible Debt across 5 years of filings, most recently posting $1.8 million for Q3 2020.

• In Q3 2020, Convertible Debt rose 1.41% year-over-year to $1.8 million; the TTM figure through Sep 2020 stood at $1.8 million (up 1.41% YoY), while the FY2019 annual figure was $1.8 million, up 4.04% from the prior year.
• Convertible Debt came in at $1.8 million for Q3 2020 at Sigyn Therapeutics, roughly flat from $1.8 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $1.8 million in Q4 2019 to a low of $17505.0 in Q2 2017.
• Average Convertible Debt over 5 years is $1.3 million, with a median of $1.7 million recorded in 2018.
• Year-over-year, Convertible Debt jumped 4570.25% in 2017 and rose 1.41% in 2020.
• Over 5 years, Convertible Debt stood at $30780.0 in 2016, then jumped by 4570.25% to $1.4 million in 2017, then rose by 20.45% to $1.7 million in 2018, then grew by 4.04% to $1.8 million in 2019, then fell by 0.28% to $1.8 million in 2020.
• Per Business Quant data, the three most recent Convertible Debt figures were $1.8 million in Q3 2020, $1.8 million in Q2 2020, and $1.8 million in Q1 2020.